Detalles de la búsqueda
1.
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.
Breast Cancer Res Treat
; 189(1): 15-23, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34218359
2.
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Breast Cancer Res Treat
; 188(2): 477-487, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33852121
3.
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.
Cancer
; 126(24): 5239-5246, 2020 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32931029
4.
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
Breast Cancer Res
; 20(1): 52, 2018 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29898752
5.
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Cancer
; 119(15): 2675-82, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23744760
6.
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Breast Cancer Res Treat
; 138(2): 427-35, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23479422
7.
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.
Nat Commun
; 14(1): 2215, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37072398
8.
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.
NPJ Breast Cancer
; 8(1): 68, 2022 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35610260
9.
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
J Clin Oncol
; 40(3): 282-293, 2022 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34874182
10.
IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
Clin Cancer Res
; 23(15): 4203-4211, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28533226
11.
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.
J Natl Cancer Inst
; 109(2)2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27794124
12.
Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
J Clin Oncol
; 34(29): 3502-3510, 2016 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27458302
13.
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.
Cancer Res
; 76(13): 3702-10, 2016 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27197192
14.
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
J Clin Oncol
; 33(7): 701-8, 2015 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25605861
15.
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.
Cancer Immunol Res
; 2(10): 962-9, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24989892
16.
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
Clin Cancer Res
; 19(20): 5798-807, 2013 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23965903
17.
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
J Natl Cancer Inst
; 104(2): 159-62, 2012 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-22138096
18.
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.
Clin Cancer Res
; 17(22): 7183-93, 2011 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21976532
19.
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
J Clin Oncol
; 28(28): 4307-15, 2010 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20697084
Resultados
1 -
19
de 19
1
Próxima >
>>